Updated September 10, 2026
Retatrutide remains an investigational medicine, not an approved Canadian pharmacy treatment. There is no verified Canadian launch date or retail price to quote. If you are searching for “reta” or “retatrutide Canada,” the important distinction is between a medicine being studied and an unapproved product being sold online.
Retatrutide has produced substantial weight loss in clinical trials, but those results do not establish that it is safe or appropriate for an individual patient. This guide separates Canadian access, research findings and unanswered safety questions.
Canadian availability · What is reta? · Clinical trials · Trial results · Side effects · Cost · Treatment options
Is Retatrutide Available in Canada?
Retatrutide is not an approved option for routine prescribing in Canada. Health Canada explicitly lists retatrutide among the unauthorized injectable peptides in its April 9, 2026 safety advisory.
A clinical trial result, an anticipated regulatory filing and a Canadian approval are different milestones. This article does not predict a 2027 approval or pharmacy launch. A reliable availability update needs a confirmed Canadian regulatory decision, followed by information about supply.
Lilly Canada’s August 13, 2026 safety notice also states that retatrutide has no Health Canada approval and cannot lawfully be sold to consumers. Online availability is not evidence of approval.
Where Can You Buy Retatrutide?
Do not buy or use unauthorized retatrutide products, including vials labelled “research use only.” Health Canada warns that this label does not exempt a product from regulation. Unapproved products may contain the wrong amount of an ingredient, contaminants or ingredients not listed on the label.
Only buy prescription medicines from licensed pharmacies. Authorized Canadian drugs carry an eight-digit Drug Identification Number (DIN). If you have used an unauthorized peptide and feel unwell or have concerns, contact a healthcare professional promptly.
Can You Join a Retatrutide Clinical Trial in Canada?
Research participation depends on a study’s current recruitment status, location and eligibility requirements. Use Lilly’s official trial finder to check current listings, then ask the study team about eligibility. A listing in search results does not mean enrolment is open or that you will receive the study medicine.
For example, the retatrutide study for obesity or overweight with chronic low back pain was marked “completed enrollment” when checked on September 10, 2026. It includes a placebo group. Walk In does not enrol patients in this trial or provide access to retatrutide.
What Is Retatrutide, or “Reta”?
Retatrutide, also called LY3437943, is a once-weekly injectable medicine under investigation by Eli Lilly. “Reta” is an informal abbreviation, not evidence that a product is authentic.
It is called a triple agonist because it activates GIP, GLP-1 and glucagon receptors. The original development study included laboratory research, animal experiments and an early human trial. Findings about energy expenditure in mice should not be presented as a guaranteed calorie-burning effect in people. Having three receptor targets does not by itself establish greater benefit or fewer side effects than another treatment.
How Much Weight Loss Has Retatrutide Produced in Trials?
Two placebo-controlled Phase 3 reports illustrate why the population, duration and analysis matter:
- TRIUMPH-4: In 445 adults with obesity or overweight and knee osteoarthritis, without diabetes, average weight loss at 68 weeks was 28.7% with 12 mg versus 2.1% with placebo under the efficacy analysis. The treatment-regimen analysis reported 23.7% versus 4.6%. These are results from Lilly’s December 11, 2025 report, not a promise of an individual outcome.
- TRIUMPH-1: In adults with obesity or overweight and a weight-related condition, without diabetes, average weight loss at 80 weeks was 28.3% with 12 mg versus 2.2% with placebo under the efficacy analysis. The treatment-regimen result was 25.0% versus 3.9%. See Lilly’s May 21, 2026 report.
The efficacy analysis estimates the effect under specified treatment-adherence assumptions; the treatment-regimen analysis includes outcomes regardless of adherence. Neither is a guaranteed real-world result. Both reports are sponsor announcements. These examples are not an exhaustive review of the development programme.
What Did the Newer TRIUMPH-2 and TRIUMPH-3 Reports Find?
In Lilly’s July 23, 2026 announcement, average weight loss at 80 weeks with 12 mg was 20.8% versus 4.0% with placebo in TRIUMPH-2 (overweight or obesity with type 2 diabetes), and 22.6% versus 3.2% in TRIUMPH-3 (severe obesity with established cardiovascular disease). These are efficacy-estimand results under treatment-adherence assumptions.
Full peer-reviewed results were pending in that announcement. Gastrointestinal adverse events and altered skin sensation were reported; at 12 mg, adverse events led to discontinuation in 7.7% versus 4.9% in TRIUMPH-2 and 13.5% versus 4.8% in TRIUMPH-3. These findings do not establish cardiovascular protection or superiority to another drug.
Is Retatrutide Better Than Semaglutide or Tirzepatide?
These trials compared retatrutide with placebo, not with semaglutide, tirzepatide or bariatric surgery. Comparing percentages across separate studies does not establish that one treatment is superior: participants, follow-up time, doses and statistical methods differ.
A larger percentage in a separate trial does not tell you how much extra weight you would lose by switching treatments. Treatment choices require evidence about benefits, risks and the particular person, not just a headline percentage.
Does Retatrutide Cure Fatty Liver Disease?
No cure has been established by the cited study. In a 98-participant Phase 2 liver-fat substudy, 86% of participants assigned 12 mg had MRI-measured liver fat below 5% at 24 weeks. This imaging threshold is not proof that liver inflammation or scarring resolved, and it is not a Canadian treatment approval for liver disease.
What Side Effects Have Been Reported?
In TRIUMPH-1, common adverse events included nausea, diarrhea, constipation and vomiting. At 12 mg, altered skin sensation (dysesthesia) occurred in 12.5% versus 0.9% with placebo; 11.3% stopped because of adverse events versus 4.9% with placebo. These figures come from the same sponsor report.
TRIUMPH-4 reported dysesthesia in 20.9% at 12 mg versus 0.7% with placebo. Rates from one study should not be treated as universal. The studies do not establish that the glucagon component caused these events. Trial findings also do not establish the safety of unapproved online products.
What Is the Retatrutide Dose?
There is no approved Canadian prescribing schedule to follow. The doses discussed here describe supervised research, not self-injection instructions. Do not use trial doses to calculate a dose, mix an online vial or design an escalation schedule.
Can You Switch From Ozempic or Mounjaro to Retatrutide?
This article cannot provide a validated switching regimen. Shared receptor activity is not a sufficient reason to assume that a transition is safe. Do not stop or change a prescribed medicine to use an unapproved peptide; discuss treatment concerns with your prescriber.
How Much Will Retatrutide Cost in Canada?
No verified Canadian retail price or coverage decision is available for this article to report. Predictions about a future price or provincial coverage should not guide a treatment budget.
For an available medicine, ask your pharmacist about the specific product, dose, dispensing fees and your plan’s coverage. Coverage for one drug or indication does not establish coverage for another.
What Can You Discuss With a Physician Now?
You do not need a predicted retatrutide launch date to discuss weight-management concerns. A physician can assess your health history, goals and treatment options, including whether medication is appropriate. Product-specific indications matter; medicines with related ingredients are not automatically interchangeable.
For background before that conversation, read our guides to weight loss medication in Canada, Wegovy and Zepbound. These guides do not replace an individual assessment.
Walk In connects eligible patients in selected Metro Vancouver communities with physicians for phone or video appointments. The physician provides medical care and determines whether a prescription or in-person assessment is appropriate. Check current eligibility and appointment availability before booking. Booking through Walk In does not provide access to retatrutide or guarantee a prescription.
Speak With a Physician About Weight Loss Treatment
Please note:
Walk In does not provide medical advice. The contents of this website, including text, graphics, images and any other material are intended for informational and educational purposes only and are not intended to substitute for professional medical advice, diagnosis or treatment. Although efforts are taken to keep any medical information on the website updated, we cannot guarantee that the information on our website is correct or reflects the most up-to-date medical information.
Please consult your physician for medical advice. Always seek the advice of a physician or other qualified healthcare provider with any questions regarding a medical condition. Never disregard or delay seeking professional medical advice or treatment because of something you have read on this website or on the internet.
